Stock Traders Purchase High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the target of some unusual options trading on Wednesday. Stock traders acquired 1,885 put options on the stock. This represents an increase of approximately 1,101% compared to the typical volume of 157 put options.

Institutional Investors Weigh In On Evelo Biosciences

Institutional investors have recently modified their holdings of the stock. Shay Capital LLC bought a new stake in shares of Evelo Biosciences in the 4th quarter valued at approximately $30,000. Barclays PLC raised its position in Evelo Biosciences by 654.2% during the 4th quarter. Barclays PLC now owns 22,641 shares of the company’s stock valued at $36,000 after purchasing an additional 19,639 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Evelo Biosciences in the 1st quarter valued at $38,000. Boothbay Fund Management LLC purchased a new position in shares of Evelo Biosciences in the 4th quarter valued at $85,000. Finally, Man Group plc purchased a new position in shares of Evelo Biosciences in the 4th quarter valued at $85,000. 0.31% of the stock is owned by institutional investors.

Evelo Biosciences Price Performance

NASDAQ:EVLO opened at $0.04 on Thursday. The firm has a market capitalization of $834,171.00, a price-to-earnings ratio of 0.00 and a beta of 2.03. Evelo Biosciences has a 1 year low of $0.03 and a 1 year high of $13.93. The business has a 50 day simple moving average of $0.05 and a 200-day simple moving average of $0.43.

About Evelo Biosciences

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.